Austrianova

What Austrianova does

Austrianova (legal entity: SGAustria Pte. Ltd.) is a Singapore-headquartered biotechnology company that develops and commercializes proprietary cell-encapsulation platforms — Cell-in-a-Box® for mammalian (human and animal) cells and Bac-in-a-Box® for bacteria and yeast — using porous cellulose sulphate polymer capsules (and the Gel8 cotton-derived polymer for the bacterial variant). The Cell-in-a-Box® capsule protects implanted cells from immune rejection while permitting diffusion of nutrients, waste, and biologically synthesized molecules; Bac-in-a-Box® provides stomach-acid protection and ambient-temperature storage, claimed at 10,000x better acid protection than competing technologies. The company supports these platforms with a GMP-compliant manufacturing stack (GMP4Cells) offering Master Cell Bank and Working Cell Bank production, Fill and Finish, cell-line development (including a λ-Integrase transgenesis platform for stable producer cell lines), stem cell manufacturing, Pep-in-a-Box® enzyme encapsulation, and in-house sterility/mycoplasma/endotoxin testing. Manufacturing is performed at a Thai-FDA-licensed, ISO 9001:2015-certified facility at Thailand Science Park with annual capacity measured in thousands of syringes/vials per campaign, and the technology is the subject of a US FDA Drug Master File already cross-referenced in PharmaCyte's pancreatic-cancer IND.

Austrianova operates a B2B, project- and contract-based commercial model with three reinforcing revenue streams: (i) contract manufacturing and R&D services paid via project fees and milestone payments; (ii) licensing of Cell-in-a-Box® and Bac-in-a-Box® IP to partners, generating upfront fees, development/regulatory milestones, and royalties on net sales; and (iii) co-development partnerships where Austrianova contributes technology and manufacturing in exchange for development funding and future commercial payments. Customers and partners span pharmaceutical and biotech companies (Avaí Bio via the Klothonova 50/50 JV; PharmaCyte Biotech; Kingen Biotech), cosmeceuticals (L'Oreal), agriculture/livestock (ProAgni for methane-reducing cattle-feed additives), and academic medicine (San Raffaele University and Research Hospital for multiple myeloma; University of Veterinary Medicine Vienna for cancer encapsulated-cell studies). The company has 11–50 employees and offices in Singapore (HQ plus Bac-in-a-Box® R&D), Thailand (GMP manufacturing), and Germany (Munich/Martinsried subsidiary). It is privately held, previously operating as SG Austria, and has received preferred equity investment from Checkmate Capital Group, whose CEO was appointed to the board in April 2026.

Name

Austrianova

Legal name

SGAustria Pte. Ltd.

Website

https://austrianova.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Austrianova is a Singapore-headquartered B2B biotechnology company that develops proprietary cell-encapsulation platforms (Cell-in-a-Box® for mammalian cells, Bac-in-a-Box® for bacteria/yeast) and provides GMP4Cells manufacturing services to pharmaceutical, biotech, cosmeceutical, agricultural, and academic partners globally.

Ownership category

akta.pro rank

Product category

Cell Encapsulation & GMP Cell Manufacturing Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

akta.pro secondary industries

Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG), Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC), Culture Carriers & Encapsulation Systems (Cryoprotectants, Microencapsulation, Delivery Matrices) (AFAJAJAK)

Keywords

• Cell encapsulation technology
• GMP cell manufacturing
• Cell therapy services
• Probiotic encapsulation
• Cell line development

Headquarters

HQ city

Vienna

HQ country

Austria

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. B2B Contract Manufacturing Services: Austrianova provides GMP cell banking, cell line development, and encapsulated cell manufacturing services to pharmaceutical, biotech, and life sciences companies on a project contract basis. Services include Master Cell Bank and Working Cell Bank production, Fill and Finish, and R&D services. Revenue is generated through project fees, milestone payments, and service contracts.
2. Licensing and Technology Royalties: Austrianova licenses its Cell-in-a-Box® and Bac-in-a-Box® encapsulation technologies to partners for development and commercialization of therapeutic and commercial products. Revenue includes upfront licensing fees, milestone payments tied to development and regulatory achievements, and ongoing royalties on net sales.
3. Product Development Partnerships: Joint development programs and co-development agreements with partners (e.g., San Raffaele Hospital, ProAgni) where Austrianova provides encapsulation technology and manufacturing capabilities in exchange for development funding and future commercial payments.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Austrianova develops and commercializes proprietary cell encapsulation technologies — Cell-in-a-Box® for mammalian cells and Bac-in-a-Box® for bacteria and yeast — that protect living cells from immune rejection and environmental stress, and provides GMP-compliant cell banking (Master/Working Cell Bank), Fill and Finish, cell line development, and allogenic stem cell manufacturing services. Offerings are delivered to pharmaceutical, biotech, agriculture, aquaculture, food, and cosmeceutical clients via licensing agreements, contract manufacturing, and joint development partnerships.

Product overview

Austrianova is a biotechnology company offering cell encapsulation and manufacturing services through two core proprietary platforms: Cell-in-a-Box® for mammalian cell encapsulation and Bac-in-a-Box® for bacterial/yeast encapsulation. These platforms are supported by GMP4Cells services including cell banking, cell line development, and stem cell manufacturing. The company operates facilities in Singapore, Thailand, and Germany, providing B2B services to pharmaceutical and biotech partners for applications including cell therapy, probiotics, cancer treatment, and metabolic disease therapies.

Differentiator

Problem solved

Functional benefit

Brands

• Cell-in-a-Box®: Proprietary cell encapsulation technology for protecting living mammalian cells from immune rejection for therapeutic applications.
• Bac-in-a-Box®
• Pep-in-a-Box
• GMP4Cells

Products and services

• Cell-in-a-Box®

Quantifiable outcome

• Bac-in-a-Box provides 10,000x better acid protection than competing technologies
• +2 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Eight partnerships are on record, tiered core, minor and major.

• Klothea Bio Inc.coreOEM/ Whitelabel/ Licensing Partner · 18 November 2025Exclusive worldwide license granted to Klothonova (the Austrianova-Avaí Bio JV) to develop, manufacture, and commercialize Klothea Bio's proprietary Klotho-producing cell line using Cell-in-a-Box® encapsulation technology. The agreement includes milestone payments tied to development and regulatory achievements and royalties on net sales.
• University of Veterinary Medicine, ViennaminorStrategic or Co-development Partner · 19 September 2025Collaborative research partner on encapsulated cell therapy for cancer. Published joint peer-reviewed study demonstrating long-term survival of encapsulated cells and metronomic ifosfamide activation in pancreatic cancer models (Life journal, 2023).
• Avaí Bio, Inc. (formerly Avant Technologies)coreStrategic or Co-development Partner · 18 September 202550/50 joint venture Klothonova established in September 2025 as a Nevada-based company focused on developing encapsulated cell-based α-Klotho anti-aging therapies. Austrianova contributes its Cell-in-a-Box® IP and manufacturing; Avaí Bio provides capital and resources. The JV secured an exclusive worldwide license from Klothea Bio in November 2025 for Klotho-producing cell lines. A GMP Master Cell Bank was completed in May 2026.
• ProAgnimajorOEM/ Whitelabel/ Licensing Partner · 2 August 2023Licensing and manufacturing agreement for development and commercialization of shelf-stable probiotic additives for cattle feed and other farm animals using Bac-in-a-Box® technology. Aims to reduce methane emissions and improve production efficiency in livestock. Austrianova provides encapsulation manufacturing; ProAgni provides bacterial strains active in the rumen.
• San Raffaele University and Research HospitalmajorStrategic or Co-development Partner · 18 May 2023Joint development program for multiple myeloma using Bac-in-a-Box® to deliver Prevotella melaninogenica bacteria to prevent progression from smouldering to aggressive disease. San Raffaele provides scientific expertise in immunology; Austrianova provides encapsulation technology for stomach acid protection and delivery.
• L'OrealminorOEM/ Whitelabel/ Licensing Partner · 21 December 2022Existing contract for Bac-in-a-Box® technology application in cosmetics extended during 2022.
• Kingen BiotechminorStrategic or Co-development Partner · 21 December 2022Alliance formed in 2022 as part of Austrianova's expanding partner network in the cell therapy/regenerative medicine space.
• Leave a Nest / Thailand Life Sciences ClusterminorStrategic or Co-development Partner · 21 December 2022Austrianova participates as a founder member of the Thailand Life Sciences Cluster and as a member of the Leave a Nest family, supporting connections in the Southeast Asian biotech ecosystem.

Scale indicators6 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• PharmaCyte Biotech: Clinical-stage oncology developer whose lead pancreatic cancer IND directly references Austrianova's Cell-in-a-Box® DMF. PharmaCyte is essentially a license-customer for Austrianova's encapsulation platform and the most direct downstream commercial proof point.
• Living Cell Technologies: Clinical-stage company developing DIABECELL encapsulated porcine islet cells for type 1 diabetes; a long-standing direct peer in the encapsulated living-cell therapy category, targeting overlapping indications to Cell-in-a-Box® metabolic programs.
• Sigilon Therapeutics: Develops encapsulated cell therapies (notably for type 1 diabetes and rare diseases) using proprietary Afibromer spheres — a direct functional analog to Cell-in-a-Box® in the immuno-protected cell therapy space.
• Betalin Therapeutics: Israeli biotech developing an engineered micro-pancreas using encapsulated islet cells for insulin-dependent diabetes; competes with Austrianova in the same encapsulated cell-therapy-for-metabolic-disease niche.
• Diatranz Otsuka Limited (DOL): New Zealand/Australia-based developer of encapsulated porcine islet cell therapy (DIABECELL) for type 1 diabetes; another direct encapsulation-therapeutics peer with GMP cell banking and clinical experience overlapping Austrianova's.

Broad incumbents

• Lonza Cell & Gene Technologies: Global CDMO incumbent with end-to-end cell and gene therapy manufacturing services. Lonza competes with Austrianova's GMP4Cells offering for outsourced cell banking and fill-finish contracts, but at much larger scale and broader scope.
• Catalent (cell therapy): Major CDMO with growing cell therapy manufacturing footprint and iPSC platform. Overlaps with Austrianova's GMP4Cells services for biotech partners seeking outsourced encapsulation-adjacent manufacturing capacity.
• Evotec (cell therapy CDMO): European-headquartered contract development and manufacturing organization with cell therapy capabilities. Competes for European and global GMP cell therapy manufacturing contracts that Austrianova also targets.

Others

• Cryoport Systems: Specialized cold-chain logistics provider for cell and gene therapies. Not a competitor but a complementary enabler of Austrianova's ambient-storage value proposition, often serving the same biotech customers.

Emerging players

• enGene: Clinical-stage gene therapy delivery company developing localized, immune-shielded therapeutics using its EGEN™ platform — an emerging encapsulation-adjacent delivery technology with overlapping therapeutic indications to Cell-in-a-Box®.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/austrianovast
• Facebookfacebook.com/austrianova
• LinkedInlinkedin.com/company/austrianova
• TikToktiktok.com/@austrianova

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries4 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Austrianova